This is why Amanda Oliver, 31, a career consultant in Charleston, SC, pops a CBD gummy bear each night before bed. “I used to lie there tossing and turning as my mind raced from work projects to whether I had set the home alarm,” Oliver says. One piece of candy with 15 milligrams (mg) of CBD is enough to shut off her brain and facilitate sleep. She also swears by the CBD oil she takes at the height of her period, which she says quells her debilitating cramps.
Over the past few years, increasing public and political pressure has supported legalization of medical marijuana. One of the main thrusts in this effort has related to the treatment of refractory epilepsy—especially in children with Dravet syndrome—using cannabidiol (CBD). Despite initiatives in numerous states to at least legalize possession of CBD oil for treating epilepsy, little published evidence is available to prove or disprove the efficacy and safety of CBD in patients with epilepsy. This review highlights some of the basic science theory behind the use of CBD, summarizes published data on clinical use of CBD for epilepsy, and highlights issues related to the use of currently available CBD products.
I recently was a guest at a medical marijuana educational event that highlighted the work of researcher Michael Backes. During his presentation he made a statement about CBD that I have never heard anywhere else that CBD is “regulating” (my word) the effects of THC. I asked the Nurse Practitioner at the event, Ivy Lou Hibbitt of Certicann.com, what he meant by that and she said it was her understanding of Michael’s comment that he takes CBD to reduce the psychoactive effects of THC. Has this property of CBD, that it can lessen psychoactive effects, ever been researched elsewhere?
The heat is very much on CBD oil sellers these days as the FDA continues to crack down on companies selling “questionable” (to put it nicely) hemp-based products. In fact, since 2015 – when the FDA first issued warning letters to multiple CBD sellers – the industry has been forced to clean up its act, at least in terms of manufacturing operations and brand transparency.
17. Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, Woodcock H, Dorward P, Pigliacampo B, Close S, Platt B, Riedel G. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behavior. Psychopharmacology (Berl) 2012;219:859–873. [PubMed] [Google Scholar]
Another field in which CBD is creating a buzz is in the area of mood disorders like anxiety and depression. Both conditions have been treated with a variety of medications, courtesy of Big Pharma, that have had varying levels of success. Again, the long list of side effects can be off-putting to someone who just wants to get through the day without the sweaty tension of anxiety or the gray haze of depression.